We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Product Safety Report for Gluta White Anti-Acne Cream presenting a high chemical risk.
The review of the safety of isotretinoin has concluded.
The updated safety measures will strengthen the MHRA’s ability to monitor safe prescribing while supporting patient access to treatment across all age groups.
We are seeking views on a proposal to make Acnecide Face 5% w/w Gel and Acnecide Face Wash 5% w/w Gel available from general sales outlets.
Call for information to support a review of isotretinoin, a treatment for severe acne. This review is being undertaken by the Medicines and Healthcare products Regulatory Agency with advice from the Commission on Human Medicines and the Isotretinoin Expert Working...
The Commission on Human Medicines (CHM) has endorsed changes to the risk minimisation measures for isotretinoin, following a review of the impact of the measures implemented in 2023. We ask healthcare professionals to review these new measures and supporting materials...
A report on adding occupational chloracne to the list of Industrial Injuries Disablement Benefit diseases by IIAC.
Safety leaflet on topical corticosteroids and withdrawal reactions to help patients and their carers to use these medicines safely.
This professional resource outlines the importance of infection prevention and control and how it can contribute to reducing antimicrobial resistance (AMR).
As with any medicine, the MHRA will keep the safety and effectiveness of deuruxolitinib under close review.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab and requires JavaScript).